AMLX
Price
$30.14
Change
-$0.46 (-1.50%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
3.84B
42 days until earnings call
Intraday BUY SELL Signals
ERAS
Price
$14.52
Change
+$0.58 (+4.16%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
4.88B
48 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMLX vs ERAS

AMLX vs ERAS Comparison Chart in %
View a ticker or compare two or three
VS
AMLX vs. ERAS commentary
Sep 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a StrongBuy and ERAS is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
TECHNICAL ANALYSIS
Technical Analysis
AMLXERAS
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 23 days ago
80%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 7 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Sep 24, 2026
Stock price -- (AMLX: $30.60 vs. ERAS: $13.94)
Brand notoriety: AMLX and ERAS are both not notable
AMLX represents the Pharmaceuticals: Generic, while ERAS is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AMLX: 74% vs. ERAS: 98%
Market capitalization -- AMLX: $3.84B vs. ERAS: $4.88B
AMLX [@Pharmaceuticals: Generic] is valued at $3.84B. ERAS’s [@Biotechnology] market capitalization is $4.88B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $66.17B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.87B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.15B. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMLX’s FA Score shows that 0 FA rating(s) are green while ERAS’s FA Score has 0 green FA rating(s).

  • AMLX’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 0 green, 5 red.
According to our system of comparison, both AMLX and ERAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMLX’s TA Score shows that 4 TA indicator(s) are bullish while ERAS’s TA Score has 4 bullish TA indicator(s).

  • AMLX’s TA Score: 4 bullish, 4 bearish.
  • ERAS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, AMLX is a better buy in the short-term than ERAS.

Price Growth

AMLX (@Pharmaceuticals: Generic) experienced а -6.21% price change this week, while ERAS (@Biotechnology) price change was -9.21% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.91%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was +42.50%.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.84%. For the same industry, the average monthly price growth was -10.68%, and the average quarterly price growth was +8.45%.

Reported Earning Dates

AMLX is expected to report earnings on Nov 05, 2026.

ERAS is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+3.91% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (-1.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
AMLX
Daily Signal:
Gain/Loss:
ERAS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DON55.15-0.34
-0.61%
WisdomTree U.S. MidCap Dividend Fund (DON)
MYCM23.67-0.23
-0.96%
State Street My2033 Corporate Bond ETF (MYCM)
FGSM34.66-0.49
-1.40%
Frontier Asset Global Small-Cap Equity ETF
MINV49.18-0.98
-1.95%
Matthews Asia Innovators Active ETF (MINV)
MSTU45.01-2.71
-5.68%
T-Rex 2X Long MSTR Daily Target ETF (MSTU)

AMLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMLX has been loosely correlated with OCUL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMLX jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMLX
1D Price
Change %
AMLX100%
-7.26%
OCUL - AMLX
46%
Loosely correlated
-4.76%
LRMR - AMLX
45%
Loosely correlated
+1.18%
JAZZ - AMLX
43%
Loosely correlated
-2.37%
RGNX - AMLX
43%
Loosely correlated
-7.98%
IDYA - AMLX
43%
Loosely correlated
-5.67%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with SNGX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then SNGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-10.32%
SNGX - ERAS
50%
Loosely correlated
+0.03%
REPL - ERAS
42%
Loosely correlated
-3.79%
AMLX - ERAS
39%
Loosely correlated
-7.26%
MLTX - ERAS
36%
Loosely correlated
-3.59%
RZLT - ERAS
36%
Loosely correlated
-0.99%
More